| # | Title | Journal | Year | Citations |
|---|
| 1 | Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study | Lancet Rheumatology, The | 2020 | 808 |
| 2 | Tocilizumab in patients with severe COVID-19: a retrospective cohort study | Lancet Rheumatology, The | 2020 | 772 |
| 3 | Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia | Lancet Rheumatology, The | 2020 | 652 |
| 4 | Anakinra for severe forms of COVID-19: a cohort study | Lancet Rheumatology, The | 2020 | 526 |
| 5 | Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial | Lancet Rheumatology, The | 2019 | 250 |
| 6 | Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study | Lancet Rheumatology, The | 2020 | 237 |
| 7 | Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study | Lancet Rheumatology, The | 2020 | 228 |
| 8 | COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study | Lancet Rheumatology, The | 2021 | 211 |
| 9 | COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study | Lancet Rheumatology, The | 2020 | 200 |
| 10 | Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome | Lancet Rheumatology, The | 2020 | 197 |
| 11 | The immunology of COVID-19: is immune modulation an option for treatment? | Lancet Rheumatology, The | 2020 | 192 |
| 12 | The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements | Lancet Rheumatology, The | 2020 | 182 |
| 13 | Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study | Lancet Rheumatology, The | 2021 | 179 |
| 14 | Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine | Lancet Rheumatology, The | 2021 | 176 |
| 15 | GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study | Lancet Rheumatology, The | 2020 | 173 |
| 16 | Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries | Lancet Rheumatology, The | 2020 | 172 |
| 17 | Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial | Lancet Rheumatology, The | 2020 | 148 |
| 18 | Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study | Lancet Rheumatology, The | 2021 | 140 |
| 19 | The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study | Lancet Rheumatology, The | 2021 | 132 |
| 20 | Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial | Lancet Rheumatology, The | 2020 | 130 |
| 21 | Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies | Lancet Rheumatology, The | 2021 | 130 |
| 22 | COVID-19 vasculitis and novel vasculitis mimics | Lancet Rheumatology, The | 2021 | 125 |
| 23 | Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study | Lancet Rheumatology, The | 2022 | 122 |
| 24 | Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout | Lancet Rheumatology, The | 2021 | 121 |
| 25 | Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis | Lancet Rheumatology, The | 2021 | 121 |
| 26 | Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment | Lancet Rheumatology, The | 2020 | 119 |
| 27 | Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study | Lancet Rheumatology, The | 2020 | 117 |
| 28 | COVACTA trial raises questions about tocilizumab's benefit in COVID-19 | Lancet Rheumatology, The | 2020 | 111 |
| 29 | COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study | Lancet Rheumatology, The | 2020 | 108 |
| 30 | Canakinumab in a subgroup of patients with COVID-19 | Lancet Rheumatology, The | 2020 | 106 |
| 31 | COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study | Lancet Rheumatology, The | 2020 | 105 |
| 32 | Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial | Lancet Rheumatology, The | 2021 | 105 |
| 33 | Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases | Lancet Rheumatology, The | 2021 | 97 |
| 34 | Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative | Lancet Rheumatology, The | 2022 | 96 |
| 35 | Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study | Lancet Rheumatology, The | 2020 | 91 |
| 36 | Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study | Lancet Rheumatology, The | 2022 | 88 |
| 37 | Preventing COVID-19-induced pneumonia with anticytokine therapy | Lancet Rheumatology, The | 2020 | 85 |
| 38 | Imperfect storm: is interleukin-33 the Achilles heel of COVID-19? | Lancet Rheumatology, The | 2020 | 84 |
| 39 | Management of IgG4-related disease | Lancet Rheumatology, The | 2019 | 83 |
| 40 | Risk factors for dislocation after primary total hip replacement: a systematic review and meta-analysis of 125 studies involving approximately five million hip replacements | Lancet Rheumatology, The | 2019 | 81 |
| 41 | Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial | Lancet Rheumatology, The | 2019 | 78 |
| 42 | Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study | Lancet Rheumatology, The | 2021 | 77 |
| 43 | Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials | Lancet Rheumatology, The | 2019 | 76 |
| 44 | COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses | Lancet Rheumatology, The | 2021 | 76 |
| 45 | Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study | Lancet Rheumatology, The | 2021 | 73 |
| 46 | Perspective of patients with autoimmune diseases on COVID-19 vaccination | Lancet Rheumatology, The | 2021 | 72 |
| 47 | Too long to wait: the impact of COVID-19 on elective surgery | Lancet Rheumatology, The | 2021 | 71 |
| 48 | Viral arthritis and COVID-19 | Lancet Rheumatology, The | 2020 | 70 |
| 49 | Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study | Lancet Rheumatology, The | 2021 | 69 |
| 50 | Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study | Lancet Rheumatology, The | 2020 | 68 |
